The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Mitch Dowsett

Department of Biochemistry

Royal Marsden Hospital and Breakthrough Breast Cancer Centre

Fulham Rd

London SW3 6JJ

UK

[email]@icr.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Biochemistry, Royal Marsden Hospital and Breakthrough Breast Cancer Centre, Fulham Rd, London SW3 6JJ, UK. 2011
  • Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom. 2004 - 2010
  • Royal Marsden Hospital, Wolfson Institute for Preventive Medicine, Queen Mary University of London London. 2010
  • The Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK. 2007
  • Royal Marsden Hospital London, SW3 6JJ United Kingdom. 2005

References

  1. Assessment of ki67 in breast cancer: recommendations from the international ki67 in breast cancer working group. Dowsett, M., Nielsen, T.O., A'hern, R., Bartlett, J., Coombes, R.C., Cuzick, J., Ellis, M., Henry, N.L., Hugh, J.C., Lively, T., McShane, L., Paik, S., Penault-Llorca, F., Prudkin, L., Regan, M., Salter, J., Sotiriou, C., Smith, I.E., Viale, G., Zujewski, J.A., Hayes, D.F. J. Natl. Cancer Inst. (2011) [Pubmed]
  2. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Dowsett, M., Cuzick, J., Ingle, J., Coates, A., Forbes, J., Bliss, J., Buyse, M., Baum, M., Buzdar, A., Colleoni, M., Coombes, C., Snowdon, C., Gnant, M., Jakesz, R., Kaufmann, M., Boccardo, F., Godwin, J., Davies, C., Peto, R. J. Clin. Oncol. (2010) [Pubmed]
  3. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E.A., Salter, J., Quinn, E., Dunbier, A., Baum, M., Buzdar, A., Howell, A., Bugarini, R., Baehner, F.L., Shak, S. J. Clin. Oncol. (2010) [Pubmed]
  4. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., Viale, G., Gelber, R.D., Piccart-Gebhart, M., Leyland-Jones, B. J. Clin. Oncol. (2009) [Pubmed]
  5. Who would have thought a single Ki67 measurement would predict long-term outcome?. Dowsett, M., A'Hern, R., Salter, J., Zabaglo, L., Smith, I.E. Breast Cancer Res. (2009) [Pubmed]
  6. The potential of new technologies/approaches. Introduction to Sessions 3 and 4. Dowsett, M. Breast Cancer Res. (2009) [Pubmed]
  7. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., Bishop, H., Ellis, I., Larsimont, D., Sasano, H., Carder, P., Cussac, A.L., Knox, F., Speirs, V., Forbes, J., Buzdar, A. J. Clin. Oncol. (2008) [Pubmed]
  8. Optimizing the implementation of future treatment using surrogate end-points. Dowsett, M. Breast Cancer Res. (2008) [Pubmed]
  9. International Web-based consultation on priorities for translational breast cancer research. Dowsett, M., Goldhirsch, A., Hayes, D.F., Senn, H.J., Wood, W., Viale, G. Breast Cancer Res. (2007) [Pubmed]
  10. Standardization of HER2 testing: results of an international proficiency-testing ring study. Dowsett, M., Hanna, W.M., Kockx, M., Penault-Llorca, F., Rüschoff, J., Gutjahr, T., Habben, K., van de Vijver, M.J. Mod. Pathol. (2007) [Pubmed]
  11. HER2 testing in the UK: consensus from a national consultation. Dowsett, M., Hanby, A.M., Laing, R., Walker, R. J. Clin. Pathol. (2007) [Pubmed]
  12. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Dowsett, M., Smith, I.E., Ebbs, S.R., Dixon, J.M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., Walsh, G. J. Natl. Cancer Inst. (2007) [Pubmed]
  13. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Dowsett, M., Smith, I.E., Ebbs, S.R., Dixon, J.M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., Francis, S., Walsh, G., A'Hern, R. Clin. Cancer Res. (2006) [Pubmed]
  14. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Dowsett, M., Folkerd, E. Breast Cancer Res. (2005) [Pubmed]
  15. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Dowsett, M., Smith, I.E., Ebbs, S.R., Dixon, J.M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., Francis, S., Walsh, G. Clin. Cancer Res. (2005) [Pubmed]
  16. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. Dowsett, M., Ebbs, S.R., Dixon, J.M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., Francis, S., Walsh, G., Smith, I.E. J. Clin. Oncol. (2005) [Pubmed]
  17. Mechanisms of resistance to aromatase inhibitors. Dowsett, M., Martin, L.A., Smith, I., Johnston, S. J. Steroid Biochem. Mol. Biol. (2005) [Pubmed]
  18. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Dowsett, M., Johnston, S., Martin, L.A., Salter, J., Hills, M., Detre, S., Gutierrez, M.C., Mohsin, S.K., Shou, J., Allred, D.C., Schiff, R., Osborne, C.K., Smith, I. Endocr. Relat. Cancer (2005) [Pubmed]
  19. The biology of steroid hormones and endocrine treatment of breast cancer. Dowsett, M., Folkerd, E., Doody, D., Haynes, B. Breast (2005) [Pubmed]
  20. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Dowsett, M., Cuzick, J., Wale, C., Howell, T., Houghton, J., Baum, M. J. Clin. Oncol. (2005) [Pubmed]
  21. Translational research and the changing face of breast cancer. Dowsett, M. Breast Cancer Res. Treat. (2004) [Pubmed]
  22. Biomarker investigations from the ATAC trial: the role of TA01. Dowsett, M. Breast Cancer Res. Treat. (2004) [Pubmed]
  23. Designing the future shape of breast cancer diagnosis, prognosis and treatment. Dowsett, M. Breast Cancer Res. Treat. (2004) [Pubmed]
 
WikiGenes - Universities